DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly - 2 Eli Lilly’s - 1 tirzepatide - 1 Dan Skovronsky - 1 David Risinger - 1 Eli Lilly's - 1 Lilly's - 1 Lilly - 1
Top related locs:
New York City U.S San Diego
Top related orgs:
Leerink - 1 Novo Nordisk - 1 American Diabetes Association - 1 New England - 1 of Medicine - 1 Thomson - 1 & $ - 1

Search resuls for: "Dan Skovronsky"


6 mentions found


☆ Eli Lilly says weight loss drug shows promise as treatment for fatty liver disease
  + stars: | 2024-02-06 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +4 min
Eli Lilly on Tuesday said its highly popular drug used for weight loss and diabetes showed promise as a treatment for fatty liver disease in a mid-stage trial. The condition is characterized by excess fat build-up and inflammation in the liver and can lead to liver scarring, also known as fibrosis. The trial followed around 190 adults with MASH with severe stages of liver scarring, Eli Lilly executives said on an earnings call Tuesday. It was less clear how much the drug reduced liver scarring, which was the second aim of the trial. Eli Lilly is "equally encouraged" by tirzepatide's results in reducing liver scarring, the company's chief scientific officer Dan Skovronsky said on the call.
Persons: Eli Lilly’s, Eli Lilly, tirzepatide, Dan Skovronsky, David Risinger, Eli Lilly's Organizations: Leerink, Novo Nordisk Locations: New York City, U.S
☆ Lilly experimental 'triple G' obesity drug leads to 24.2% weight loss in trial
  + stars: | 2023-06-26 | by ( Deena Beasley | ) www.reuters.com   time to read: +2 min
Companies Eli Lilly and Co FollowJune 26 (Reuters) - Eli Lilly (LLY.N) on Monday said a mid-stage trial of its next-generation obesity drug candidate "triple G" showed that it led to weight loss of up to 24.2% after 48 weeks, surpassing results seen with other weight loss drugs. Lilly's Mounjaro, which is awaiting U.S. regulatory approval for treatment of obesity, targets GLP-1 as well as a second obesity-related hormone called GIP. Retatrutide targets GLP-1, GIP and the body's receptors for a third hormone, glucagon. Given the three targets, Lilly has nicknamed the drug triple G.The company reported last year that a trial of Mounjaro in people who were obese or overweight found it led to weight loss of 22.5% after 72 weeks. Lilly is conducting longer-duration phase 3 trials of retatrutide to see if weight loss might be further improved.
Persons: Eli Lilly, Lilly's, Lilly, ” Dan Skovronsky, Deena Beasley, Deepa Babington, Cynthia Osterman Organizations: American Diabetes Association, New England, of Medicine, Thomson Locations: San Diego
☆ Alzheimer’s patients may wait years to get treated with new drugs, putting them at risk of more severe disease
  + stars: | 2023-04-30 | by ( Spencer Kimball | ) www.cnbc.com   time to read: +17 min
But time spent waiting robs early patients of their memory and ability to live independently. This condition is often, though not always, a sign of early Alzheimer's disease. PET scans cumbersomeTwo types of tests can diagnosis Alzheimer's disease: PET scans and spinal taps. Early Alzheimer's disease can also be diagnosed with a spinal tap, in which fluid around the spinal cord is extracted with a catheter and tested. He believes big players like CVS will provide infusions for Alzheimer's disease on a major scale if they see there's a large and stable market.
☆ Eli Lilly Alzheimer's treatment solanezumab failed to slow disease progression
  + stars: | 2023-03-09 | by ( Spencer Kimball | ) www.cnbc.com   time to read: +3 min
Eli Lilly on Wednesday said it will halt development of its Alzheimer's treatment candidate solanezumab after the antibody failed to slow disease progression. The study enrolled more than 1,000 seniors who had normal memory and thinking function, but showed signs of brain plaque that is associated with Alzheimer's. Lilly said it did not have that data because donanemab cleared brain plaque quickly in many patients. "We remain confident in the of potential donanemab as a new treatment for people with early symptomatic Alzheimer's disease," Skovronsky said. The FDA approved Eisai's and Biogen's early Alzheimer's treatment Leqembi on an expedited basis in January.
☆ Eli Lilly is the best of both worlds — a recession-resistant stock with major growth potential
  + stars: | 2023-01-11 | by ( Kevin Stankiewicz | ) www.cnbc.com   time to read: +7 min
The year ahead is pivotal for Eli Lilly (LLY) as the pharmaceutical giant looks to advance drugs in its stellar pipeline. It's a dynamic that, in many ways, embodies the Club's thinking on Eli Lilly, one of our 10 core holdings . In the meantime, Eli Lilly is set to release Phase 3 data for a number of different studies in 2023. Eli Lilly has already asked U.S. regulators to expand the drug's approved uses to obesity, in addition to being sold as Mounjaro for type 2 diabetes. Traders work beneath monitors displaying Eli Lilly signage on the floor of the New York Stock Exchange.
Organizations: & $
☆ Eli Lilly has spent years and billions of dollars in search of an effective Alzheimer's drug. But success is not all or nothing for the stock
  + stars: | 2023-01-09 | by ( Kevin Stankiewicz | ) www.cnbc.com   time to read: +22 min
Eli Lilly (LLY) has spent decades researching Alzheimer's disease without successfully bringing to market a treatment that slows the memory-destroying condition. For Eli Lilly as a company, an Alzheimer's drug is an important pursuit. Lilly's Alzheimer's history Eli Lilly's "first real foray" into Alzheimer's came in the 1990s, according to Dr. John Sims, Eli Lilly's head of medical development for donanemab. Financial implications for Lilly LLY mountain 2021-10-08 The Club started a new position in Eli Lilly (LLY) in October 2021. The Eli Lilly logo is shown on one of the company's offices in San Diego, California, September 17, 2020.
0 next >>
Total: 6